BNCT is a biologically targeted radiation therapy that kills cancer at the cellular level. The technique uses a two-step process. In the first step, patients are injected with a tumor-targeting drug that contains non-toxic and non-radioactive boron-10. In the second step, the target area is exposed to low-energy neutrons. When the boron-10 and neutrons interact, short-range, high-energy charged particles are emitted that systemically destroy tumor cells – with minimal damage to adjacent healthy tissue and low risk of side effects. BNCT is therefore an attractive treatment modality for complicated and recurrent cancers, such as glioblastomas or head and neck cancers.
The combination of worldwide clinical interest in BNCT, advanced boron agents, modern accelerator-based neutron production technology and innovative software is paving the way for a new era in BNCT to help the fight against cancer.
The RayStation treatment planning system supports BNCT treatment planning* with tools for contouring, image importing, reporting, plan creation and evaluation, as well as support for defining BNCT-specific models of relative biological effectiveness. Under the agreement, RayStation will work in conjunction with TAE Life Sciences’ proprietary dose calculation software for the Alphabeam System, which can be configured for single- or multi-room BNCT centers.
Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.
Bruce Bauer, CEO, TAE Life Sciences, says: “The new era of accelerator-based BNCT offers a highly promising therapy for hard-to-treat cancers, both in effectiveness and reduced treatment time. We are excited to partner with RaySearch on the integration of RayStation with our compact Alphabeam System. Our partnership will help accelerate the commercialization of hospital-based BNCT and greatly benefit clinicians and cancer patients globally.”
Johan Löf, founder and CEO, RaySearch, says: “BNCT is gaining ground as an option for certain types of tumors, and we are keen to support partner companies operating in this field of radiation therapy. I am pleased to share the news of our partnership with TAE Life Sciences to advance cancer treatment.”
About TAE Life Sciences
TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy, accelerator-based neutron source – optimized for an in-hospital BNCT program that will one day treat patients with the most aggressive and recurrent cancers. TLS has assembled a world-class cross-functional team of clinicians, radiation oncologists, physicists and other researchers to bring its technology to the cancer patients who need it most. TLS’s drug and device are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at www.taelifesciences.com.